Arix Bioscience PLC (ARIX) 
Director Share Purchase 
 
21-Dec-2020 / 07:00 GMT/BST 
Dissemination of a Regulatory Announcement, transmitted by EQS Group. 
The issuer is solely responsible for the content of this announcement. 
 
*Arix Bioscience plc* 
********************* 
 
      Director Share Purchase 
 
 LONDON, 21 December 2020: Arix Bioscience plc ("Arix", LSE: ARIX), a global 
   venture capital company focused on investing in and building breakthrough 
    biotech companies, today announces that Naseem Amin, Executive Chairman, 
  purchased 183,000 ordinary shares ("Ordinary Shares") in the Company on 18 
 December 2020 at a price of 206p per share, via a corporate entity in which 
             he has a majority beneficial interest. 
 
The below notification, made in accordance with the requirements of the EU 
Market Abuse Regulation, gives further detail of the transaction in number 
of Ordinary Shares. 
 
PDMR DEALING NOTIFICATION 
Notification and public disclosure of transactions by 
persons discharging managerial responsibilities and persons 
closely associated with them 
    1     Details of the person discharging managerial 
          responsibilities / person closely associated 
   a)     Name           Naseem Amin 
    2     Reason for the notification 
   a)     Position /     Executive Chairman 
          status 
   b)     Initial        Initial Notification 
          notification / 
 
          Amendment 
    3     Details of issuer 
   a)     Name           Arix Bioscience plc 
   b)     LEI            213800OVT3AHQCXNIX43 
    4     Details of the transaction(s): section to be 
          repeated for (i) each type of instrument; (ii) each 
          type of transaction; (iii) each date; and (iv) each 
          place where transactions have been conducted 
   a)     Description of Ordinary Shares of Arix Bioscience 
          the financial  plc 
          instrument, 
          type of 
          instrument 
          Identification GB00BD045071 
          code 
   b)     Nature of the  Purchase of Ordinary Shares by Davum 
          transaction    Capital Limited, a corporate entity 
                         in which Naseem Amin has a majority 
                         beneficial interest 
   c)     Price(s) and   Price(s)           Volume(s) 
          volume(s) 
                         206.00p            183,000 
   d)     Aggregated     Aggregated price   Aggregated volume 
          information 
                         N/A (single        N/A (single 
                         transaction)       transaction) 
   e)     Date of the    18 December 2020 
          transaction 
   f)     Place of the   London Stock Exchange (XLON) 
          transaction 
 
For further information: 
 
Robert Lyne Chief Operating Officer and General Counsel +44 (0)207 290 1050 
 
      - Ends - 
 
ISIN:          GB00BD045071 
Category Code: DSH 
TIDM:          ARIX 
LEI Code:      213800OVT3AHQCXNIX43 
Sequence No.:  90018 
EQS News ID:   1156507 
 
End of Announcement EQS News Service

(END) Dow Jones Newswires

December 21, 2020 02:00 ET (07:00 GMT)